Nurix Therapeutics, Inc.NRIXEarnings & Financial Report
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel targeted protein degradation therapies for cancer, immune disorders and other serious unmet medical needs. Its core pipeline leverages proprietary E3 ubiquitin ligase modulation technology, with operations primarily based in the United States and collaborative partnerships with global pharmaceutical firms.
Revenue
$13.3M
Gross Profit
N/A
Operating Profit
$-64.7M
Net Profit
$-58.5M
Gross Margin
N/A
Operating Margin
-486.7%
Net Margin
-440.7%
YoY Growth
-12.4%
EPS
$-0.74
Nurix Therapeutics, Inc. Q4 FY2024 Financial Summary
Nurix Therapeutics, Inc. reported revenue of $13.3M (down 12.4% YoY) for Q4 FY2024, with a net profit of $-58.5M (down 39.5% YoY) (-440.7% margin).
Key Financial Metrics
| Total Revenue | $13.3M |
|---|---|
| Net Profit | $-58.5M |
| Gross Margin | N/A |
| Operating Margin | -486.7% |
| Report Period | Q4 FY2024 |
Revenue Breakdown
Nurix Therapeutics, Inc. Q4 FY2024 revenue of $13.3M breaks down across 2 segments, led by Other at $7.8M (58.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $7.8M | 58.6% |
| Sanofi Agreement | $5.5M | 41.4% |
Nurix Therapeutics, Inc. Annual Revenue by Year
Nurix Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $84.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $84.0M |
| 2024 | $54.5M |
| 2023 | $77.0M |
| 2022 | $38.6M |
Nurix Therapeutics, Inc. Quarterly Revenue & Net Profit History
Nurix Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.6M | +2.2% | $-78.2M | -576.1% |
| Q3 FY2025 | $7.9M | -37.3% | $-86.4M | -1094.8% |
| Q2 FY2025 | $44.1M | +264.3% | $-43.5M | -98.7% |
| Q1 FY2025 | $18.5M | +11.3% | $-56.4M | -305.4% |
| Q4 FY2024 | $13.3M | -12.4% | $-58.5M | -440.7% |
| Q3 FY2024 | $12.6M | -31.8% | $-49.0M | -388.9% |
| Q2 FY2024 | $12.1M | -60.6% | $-44.5M | -368.4% |
| Q1 FY2024 | $16.6M | +30.7% | $-41.5M | -250.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.6M | $12.1M | $12.6M | $13.3M | $18.5M | $44.1M | $7.9M | $13.6M |
| YoY Growth | 30.7% | -60.6% | -31.8% | -12.4% | 11.3% | 264.3% | -37.3% | 2.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $312.7M | $511.0M | $513.6M | $669.3M | $615.0M | $591.6M | $522.5M | $688.1M |
| Liabilities | $143.9M | $140.3M | $136.7M | $142.3M | $134.1M | $144.0M | $150.2M | $149.4M |
| Equity | $168.7M | $370.7M | $376.9M | $527.0M | $480.9M | $447.6M | $372.3M | $538.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-42.0M | $-39.7M | $-42.2M | $-48.8M | $-61.1M | $-63.2M | $-57.4M | $-67.8M |